5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one | 97323-08-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one
• 英文别名: 5-[[4-[(6-Hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-2-imino-1,3-thiazolidin-4-one；5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-2-imino-1,3-thiazolidin-4-one
• CAS: 97323-08-5
• 化学式: C₂₄H₂₈N₂O₄S
• 分子量: 440.563
• InChiKey: CAEMWTIZSYCXJB-UHFFFAOYSA-N

物化性质

• 沸点：
  641.0±65.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one 生成 曲格列酮
  参考文献：
  名称：

  Thiazolidine derivatives, their preparation and compositions containing

  摘要：

  分子式为（I）的化合物：##STR1## [其中：R.sup.1和R.sup.2相同或不同，分别代表氢或C.sub.1-C.sub.5烷基；R.sup.3代表氢，酰基，（C.sub.1-C.sub.6烷氧基）羰基或芳基烷氧羰基；R.sup.4和R.sup.5相同或不同，分别代表氢，C.sub.1-C.sub.5烷基或C.sub.1-C.sub.5烷氧基，或R.sup.4和R.sup.5共同代表C.sub.1 14 C.sub.4亚烷基二氧基基团；n为1、2或3；W代表--CH.sub.2--，>CO或>CH--OR.sup.6基团（其中R.sup.6代表R.sup.3定义的任何一个原子或基团，并且可以与R.sup.3相同或不同）；Y和Z相同或不同，分别代表氧或亚胺基]及其药学上可接受的盐在血液系统上具有各种有价值的治疗作用，并且可以通过将相应的卤代丙酸衍生物与硫脲反应来制备。

  公开号：

  US04572912A1
• 作为产物：
  描述：

  Ethyl 3-<4-<(6-acetoxy-2,5,7,8-tetramethylchroman-2-yl)methoxy>phenyl>-2-chloropropionate 生成 5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]-2-iminothiazolidin-4-one
  参考文献：
  名称：

  Thiazolidine derivatives, their preparation and compositions containing

  摘要：

  分子式为（I）的化合物：##STR1## [其中：R.sup.1和R.sup.2相同或不同，分别代表氢或C.sub.1-C.sub.5烷基；R.sup.3代表氢，酰基，（C.sub.1-C.sub.6烷氧基）羰基或芳基烷氧羰基；R.sup.4和R.sup.5相同或不同，分别代表氢，C.sub.1-C.sub.5烷基或C.sub.1-C.sub.5烷氧基，或R.sup.4和R.sup.5共同代表C.sub.1 14 C.sub.4亚烷基二氧基基团；n为1、2或3；W代表--CH.sub.2--，>CO或>CH--OR.sup.6基团（其中R.sup.6代表R.sup.3定义的任何一个原子或基团，并且可以与R.sup.3相同或不同）；Y和Z相同或不同，分别代表氧或亚胺基]及其药学上可接受的盐在血液系统上具有各种有价值的治疗作用，并且可以通过将相应的卤代丙酸衍生物与硫脲反应来制备。

  公开号：

  US04572912A1

文献信息

• Polymorphic forms of troglitazone having enhanced anti-diabetic activity
  申请人：Dr. Reddy's Research Foundation

  公开号：US05700820A1

  公开（公告）日：1997-12-23

  Novel polymorphic forms of Troglitazone and methods for preparing the polymorphic forms of Troglitazone. The polymorphic forms of Troglitazone can be used to treat diabetic ailments.

  Troglitazone的新型多晶型形式及其制备方法。Troglitazone的多晶型形式可用于治疗糖尿病病症。
• Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation
  作者：Takao Yoshioka、Takashi Fujita、Tsutomu Kanai、Yuichi Aizawa、Tomoyuki Kurumada、Kazuo Hasegawa、Hiroyoshi Horikoshi

  DOI：10.1021/jm00122a022

  日期：1989.2

  A series of hindered phenols were investigated as hypolipidemic and/or hypoglycemic agents with ability to inhibit lipid peroxidation. 1,3-Benzoxathioles (9 and 22), phenoxypentanoic acid (34), phenoxypentanol (35a), phenoxynonanol (35b), phenylchloropropionic acid having a chromanyl group (25), and a thiazolidine compound (27) derived from 25, all having a hindered phenol group, were prepared and examined. Compound 27 showed the expected biological properties in vivo and in vitro without any liver weight increase. Biological activities of the analogous thiazolidine compounds, 43-58, were compared. Thus, (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]- benzyl]-2,4-thiazolidinedione (27) (CS-045) was found to have all of our expected properties and was selected as a candidate for further development as a hypoglycemic and hypolipidemic agent.
• Thiazolidine derivatives, their preparation and use
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0207581B1

  公开（公告）日：1990-09-12
• Thiazolidine derivatives, their preparation and compositions containing them
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0139421B1

  公开（公告）日：1988-04-27
• JOSIOKA, TAKAO;KITADZAVA, EHJITI;KURUMADA, TOMOYUKI;YAMADZAKI, MITSURO;XA+
  作者：JOSIOKA, TAKAO、KITADZAVA, EHJITI、KURUMADA, TOMOYUKI、YAMADZAKI, MITSURO、XA+

  DOI：——

  日期：——